Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)

被引：0

作者：

Yap, Y. S. ^{[1
]}

Masuda, N. ^{[2
]}

Ito, Y. ^{[3
]}

Ishikawa, T. ^{[4
]}

Kim, S. J. ^{[5
]}

Aruga, T. ^{[6
]}

Toyama, T. ^{[7
]}

Saeki, T. ^{[8
]}

Yamanaka, T. ^{[9
]}

Saito, M. ^{[10
]}

Watanabe, J. ^{[11
]}

Takahashi, M. ^{[12
]}

Nakamura, S. ^{[13
]}

Inoue, K. ^{[14
]}

Suarez-Vizcarra, J. ^{[15
]}

He, W. ^{[15
]}

Solovieff, N. ^{[16
]}

Su, F. ^{[15
]}

Chiu, J. ^{[17
]}

机构：

[1] Natl Canc Ctr, Med Oncol, Singapore, Singapore

[2] Osaka Natl Hosp, Med Oncol, Osaka, Japan

[3] Japanese Fdn Canc Res, Canc Inst Hosp, Med Oncol, Tokyo, Japan

[4] Tokyo Med Univ Hosp, Med Oncol, Tokyo, Japan

[5] Osaka Univ Hosp, Med Oncol, Osaka, Japan

[6] Tokyo Komagome Hosp, Med Oncol, Tokyo, Japan

[7] Nagoya City Univ, Grad Sch Med Sci, Med Oncol, Nagoya, Aichi, Japan

[8] Saitama Med Univ, Med Oncol, Int Med Ctr, Saitama, Japan

[9] Kanagawa Canc Ctr, Med Oncol, Yokohama, Kanagawa, Japan

[10] Juntendo Univ Hosp, Med Oncol, Tokyo, Japan

[11] Shizuoka Canc Ctr, Med Oncol, Nagaizumi, Shizuoka, Japan

[12] Hokkaido Canc Ctr, Natl Hosp Org, Med Oncol, Sapporo, Hokkaido, Japan

[13] Showa Univ Hosp, Breast Ctr, Tokyo, Japan

[14] Saitama Canc Ctr, Med Oncol, Saitama, Japan

[15] Novartis Pharmaceut, Novartis Oncol, E Hanover, NJ USA

[16] Novartis Inst BioMed Res, Biomarkers & Diagnost Biometr, Cambridge, MA USA

[17] Queen Mary Hosp, Med Oncol, Hong Kong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

10.1093/annonc/mdy428

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

400

引用

页码：13 / +

页数：2

共 50 条

[1] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
Masuda, N.
Noguchi, S.
Ishikawa, T.
Aruga, T.
Kim, S. J.
Toyama, T.
Saeki, T.
Saito, M.
Yamanaka, T.
Watanabe, J.
Nakamura, S.
Takahashi, M.
Inoue, K.
Gounaris, I.
Han, Y.
Samant, T. S.
Gazdoiu, M.
Ito, Y.
ANNALS OF ONCOLOGY, 2018, 29
[2] First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
Hortobagyi, Gabriel N.
Paluch-Shimon, Shani
Petrakova, Katarina
Villanueva, Cristian
Chan, Arlene
Nusch, Arnd
Yap, Yoon Sim
Hart, Lowell
Favret, Anne
Marschner, Norbert
Sonke, Gabe S.
Ohnstad, Hege Oma
Arteaga, Carlos
Su, Fei
He, Wei
Miller, Michelle Kristine
Stemmer, Salomon M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, G. S.
Paluch-Shimon, S.
Campone, M.
Blackwell, K.
Andre, F.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D.
Xuan, F.
Souami, F.
Miller, M.
Germa, C.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2016, 27
[4] Ribociclib (RIB) plus fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3
Slamon, Dennis J.
Neven, Patrick
Chia, Stephen K. L.
Im, Seock-Ah
Fasching, Peter A.
DeLaurentiis, Michelino
Petrakova, Katarina
Bianchi, Giulia Valeria
Esteva, Francisco J.
Martin, Miguel
Pivot, Xavier
Vidam, Gena
Wang, Yingbo
Lorenc, Cristina Karen Rodriguez
Miller, Michelle Kristine
Taran, Tanya
Jerusalem, Guy Heinrich Maria
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
Verma, S.
Gil-Gil, M.
Hegg, R.
Wheatley-Price, P.
Kattan, J.
Bourgeois, H.
Sutradhar, S.
Miller, M.
Campone, M.
ANNALS OF ONCOLOGY, 2017, 28
[6] Ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative, advanced breast cancer (ABC) who received no prior therapy for advanced disease
Janni, W.
Nusch, A.
Grischke, E. -M
Marschner, N.
Wilke, J.
Decker, T.
Abenhardt, W.
Kurbacher, C.
Overkamp, F.
Just, M.
Kuemmel, S.
Marme, F.
Xuan, F.
Miller, M.
Sonke, G. S.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 214 - 215
[7] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
Janni, Wolfgang
Burris, Howard A.
Blackwell, Kimberly L.
Hart, Lowell L.
Chan, Arlene
Nusch, Arnd
Burdaeva, Olga Nikolaevna
Alba, Emilio
Yardley, Denise A.
Bachelot, Thomas Denis
Gil, Miguel J. Gil
Richards, Donald A.
Sparano, Joseph A.
Kattan, Joseph Gergi
Bourgeois, Hugues Pierre
El Karak, Fadi Rafic
Ramaswamy, Bhuvaneswari
Sutradhar, Santosh C.
Miller, Michelle Kristine
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Ditsch, Nina
Schmidt, Marcus
GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
[9] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
Burris, H. A.
Chan, A.
Im, S-A
Chia, S.
Tripathy, D.
Esteva, F. J.
Campone, M.
Bardia, A.
Kong, O.
Bao, W.
Diaz-Padilla, I.
Lorenc, K. Rodriguez
Yardley, D. A.
CANCER RESEARCH, 2019, 79 (04)
[10] Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).
Moy, B.
Lebrun, F.
Bellet, M.
Chow, L.
Lang, I.
Xu, B.
Badwe, R. A.
Hershman, D. L.
Leip, E.
Bardy-Bouxin, N.
Duvillie, L.
Neven, P.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →